Prevent concomitant use of tucatinib with CYP3A substrates, where by nominal focus improvements could lead to really serious or existence-threatening toxicities. If unavoidable, cut down CYP3A substrate dose In line with item labeling.darifenacin will raise the degree or outcome of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolis